Keystone Heart, A Venus Medtech Company, Announces First Commercial Case Performed Worldwide with the TriGUARD 3™ Cerebral Embolic Protection Device
July 29, 2020TAMPA, Fla., July 29, 2020 /PRNewswire/ -- Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care,
Read MoreView AllKeystone Heart, A Venus Medtech Company, Acquires 510 Kardiac Devices, Inc.
June 16, 2020TAMPA, Fla., June 16, 2020 /PRNewswire/ -- Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care,
Read MoreView AllVenus Medtech Announces Agreement to Acquire Keystone Heart, LTD
January 09, 2019
Merger Establishes US and EMEA Presence for the Preeminent Chinese Structural Heart Company
HANGZHOU, China and CAESAREA, Israel and TAMPA, Florida
Read MoreView AllCurrent Cerebral Embolic Protection Landscape
December 03, 2018Keystone Heart TriGUARD Data Review
Jeffrey Moses
Conclusions:
Overt and Covert stroke are significant complications of TAVR which may be o
Read MoreView AllREFLECT Clinical Update with TriGUARD3 Cerebral Embolic Protection Device
December 03, 2018Tamim Nazif
Conclusions:
TriGUARD 3™ offers complete 3 vessel cerebral embolic protection for TAVR
Specific design improvements optimize
Read MoreView All
Sign Up for Keystone Heart Updates
EU
US
